Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma

British Journal of Haematology

Volumn 131, Issue 3, 2005, Pages 338-340

  Bauwens, Deborah ^a   Maerevoet, Marie ^a,b   Michaux, Lucienne ^a,c   Théate, Ivan ^a   Hagemeijer, Anne ^c   Stul, Michel ^c   Danse, Etienne ^a   Costantini, Sabrina ^a   Vannuffel, Pascal ^d   Straetmans, Nicole ^e   Vekemans, Marie Christiane ^a   Deneys, Véronique ^a   Ferrant, Augustin ^a   Van Den Neste, Eric ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Clinique Saint Pierre of Ottignies   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d INSTITUTE OF PATHOLOGY AND GENETICS   (Belgium)

^e Hospital de Jolimont   (Belgium)

Author keywords

B cell non Hodgkin lymphoma; Chlorambucil; Immuno chemotherapy; Mantle cell lymphoma; Rituximab

Indexed keywords

CHLORAMBUCIL; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG SAFETY; FEMALE; HUMAN; INFECTION; MALE; MANTLE CELL LYMPHOMA; MYELODYSPLASIA; NEUTROPENIA; PRIORITY JOURNAL; RELAPSE; REMISSION; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; HEMATOLOGIC DISEASE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 33644810117     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05777.x     Document Type: Article

References (9)

1. Cheson B.D. Horning S.J. Coiffier B. Shipp M.A. Fisher R.I. Connors J.M. Lister T.A. Vose J. Grillo-Lopez A. Hagenbeek A. Cabanillas F. Klippensten D. Hiddemann W. Castellino R. Harris N.L. Armitage J.O. Carter W. Hoppe R. Canellos G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244 1253.
2. Chow K.U. Sommerlad W.D. Boehrer S. Schneider B. Seipelt G. Rummel M.J. Hoelzer D. Mitrou P.S. Weidmann E. (2002) Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica, 87, 33 43.
3. Fisher R.I. Miller T.P. O'Connor O.A. (2004) Diffuse aggressive lymphoma. Hematology (Am Soc Hematol Educ Program), 2004q1, 221 236.
4. Forstpointner R. Dreyling M. Repp R. Hermann S. Hanel A. Metzner B. Pott C. Hartmann F. Rothmann F. Rohrberg R. Bock H.P. Wandt H. Unterhalt M. Hiddemann W. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104, 3064 3071.
5. Ghielmini M. Schmitz S.F. Cogliatti S. Bertoni F. Waltzer U. Fey M.F. Betticher D.C. Schefer H. Pichert G. Stahel R. Ketterer N. Bargetzi M. Cerny T. (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of Clinical Oncology, 23, 705 711.
6. Howard O.M. Gribben J.G. Neuberg D.S. Grossbard M. Poor C. Janicek M.J. Shipp M.A. (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. Journal of Clinical Oncology, 20, 1288 1294.
7. Martinelli G. Laszlo D. Bertolini F. Pastano R. Mancuso P. Calleri A. Vanazzi A. Santoro P. Cavalli F. Zucca E. (2003) Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. British Journal of Haematology, 123, 271 277.
8. Orchard J. Garand R. Davis Z. Babbage G. Sahota S. Matutes E. Catovsky D. Thomas P.W. Avet-Loiseau H. Oscier D. (2003) A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood, 101, 4975 4981.
9. Vandenberghe E. De Wolf-Peeters C. Vaughan Hudson G. Vaughan Hudson B. Pittaluga S. Anderson L. Linch D.C. (1997) The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. British Journal of Haematology, 99, 842 847.